Evidence map›Paper›PMID 32285213›Full record

ArticleClinical and experimental nephrology2020

Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.

Akira Iguchi, Suguru Yamamoto, Akira Oda, Kenichi Tanaka, Junichiro James Kazama, Takako Saeki, Hajime Yamazaki, Ken Ishioka, Tatsuo Suzutani, Ichiei Narita

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. A guide to uraemic toxicity.Nature reviews. Nephrology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Akira IguchiDepartment of Internal Medicine, Nagaoka Red-Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan. igucci4444@yahoo.co.jp.ORCID http://orcid.org/0000-0003-0016-0875
Suguru YamamotoDivision of Blood Purification Therapy, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan.
Akira OdaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Kenichi TanakaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Junichiro James KazamaDepartment of Nephrology and Hypertension, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Takako SaekiDepartment of Internal Medicine, Nagaoka Red-Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan.
Hajime YamazakiDepartment of Internal Medicine, Nagaoka Red-Cross Hospital, 2-297-1 Sensyu, Nagaoka, Niigata, 940-2085, Japan.
Ken IshiokaDepartment of Microbiology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Tatsuo SuzutaniDepartment of Microbiology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Niigata, 951-8510, Japan.
Fukushima Medical University · JPNagaoka Red Cross Hospital · JPNiigata University Medical and Dental Hospital · JP

Funding

Kidney Foundation, Japan JKFB16-25
6 · The paper itself

Abstract

backgroundIn patients with chronic kidney disease (CKD), dysbiosis in the gastrointestinal microbiome is thought to be associated with increased production of uremic toxins, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Sucroferric oxyhydroxide (SFO), an iron-based phosphate binder, may affect the gastrointestinal microbiome and the production of uremic toxins. We aimed to examine whether SFO administration affected distribution of gastrointestinal microbiome and serum uremic toxin levels in CKD patients undergoing hemodialysis.

methodsIn this single-center, open-label, interventional study, 18 maintenance hemodialysis patients with hyperphosphatemia were prescribed with SFO. We collected serum samples before and after 3 months of administration, and serum levels of IS and PCS were measured. A control group of 20 hemodialysis patients without SFO was evaluated. We evaluated gastrointestinal microbiome of patients pre- and post-SFO administration by 16S rDNA sequencing and bioinformatics analysis.

resultsSerum IS and PCS levels were significantly elevated after administration of SFO (IS before 2.52 ± 1.60 mg/dl vs. after 3.13 ± 1.51 mg/dl, P = 0.008; PCS before 2.32 ± 2.44 mg/dl vs. after 3.45 ± 2.11 mg/dl, P = 0.002), while serum IS and PCS levels did not change in the control group. Microbiome analysis in the SFO group showed no significant change in diversity and major components in phylum, class, order, family, gene, and species.

conclusionAdministration of SFO increased the serum levels of IS and PCS with no change of major components of gastrointestinal microbiome.

Indexed as

AgedAged, 80 and overCase-Control StudiesCresolsDrug CombinationsDysbiosisFecesFerric CompoundsGastrointestinal MicrobiomeHumansIndicanMiddle AgedRenal DialysisRenal Insufficiency, ChronicSucroseSulfuric Acid Esters4-cresol sulfateCresolsDrug CombinationsFerric CompoundsIndicansucroferric oxyhydroxideSucroseSulfuric Acid EstersChronic kidney diseaseGastrointestinal microbiomeIndoxyl sulfatep-Cresyl sulfateSerum uremic toxinSucroferric oxyhydroxide

Identifiers

PMID32285213
OpenAlexW3015331333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.